AHP Enbrel Market Expansion Plans Include Up To 2.4 Mil. U.S. Patients
Executive Summary
The next step in Wyeth-Ayerst's plans to expand the market for Enbrel will be the presentation of the pivotal trial data in early rheumatoid arthritis during the upcoming American College of Rheumatology conference in Boston, Nov. 13-17.
You may also be interested in...
Wyeth Prevenar Approval Expected By End of February
Wyeth-Ayerst is expecting approval of its pneumococcal conjugate vaccine Prevenar by the end of February.
Wyeth Prevenar Approval Expected By End of February
Wyeth-Ayerst is expecting approval of its pneumococcal conjugate vaccine Prevenar by the end of February.
Immunex Novantrone MS Use Is Likely To Be Second-Line
Immunex expects Novantrone (mitoxantrone) would be used primarily as second-line therapy if approved for the treatment of multiple sclerosis.